Myoferlin plays a key role in VEGFA secretion and impacts tumor-associated angiogenesis in human pancreas cancer

International Journal of Cancer

Volumn 138, Issue 3, 2016, Pages 652-663

  Fahmy, Karim ^a   Gonzalez, Arnaud ^a   Arafa, Mohammad ^b   Peixoto, Paul ^a   Bellahcène, Akeila ^a   Turtoi, Andrei ^a   Delvenne, Philippe ^a   Thiry, Marc ^a   Castronovo, Vincent ^a   Peulen, Olivier ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

angiogenesis; exocytosis; myoferlin; pancreas ductal adenocarcinoma; VEGF

Indexed keywords

MYOFERLIN; PHOSPHOLIPID BINDING PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN A; CALCIUM BINDING PROTEIN; CD31 ANTIGEN; MEMBRANE PROTEIN; MUSCLE PROTEIN; MYOF PROTEIN, HUMAN; VEGFA PROTEIN, HUMAN;

ARTICLE; BLOOD VESSEL; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; EXOCYTOSIS; GENE; GENE EXPRESSION; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; IN VITRO STUDY; NONHUMAN; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; TUMOR GROWTH; TUMOR VOLUME; VEGFA GENE; ADENOCARCINOMA; NEOVASCULARIZATION, PATHOLOGIC; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; SECRETION (PROCESS); TUMOR CELL LINE; VASCULARIZATION;

ADENOCARCINOMA; ANTIGENS, CD31; CALCIUM-BINDING PROTEINS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MEMBRANE PROTEINS; MUSCLE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84955632993     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29820     Document Type: Article

References (50)

1. Doherty KR, Demonbreun AR, Wallace GQ, et al., The endocytic recycling protein EHD2 interacts with myoferlin to regulate myoblast fusion. J Biol Chem 2008; 283: 20252-60.
2. Cipta S, Patel HH., Molecular bandages: inside-out, outside-in repair of cellular membranes. Focus on "Myoferlin is critical for endocytosis in endothelial cells." Am J Physiol Cell Physiol 2009; 297: C481-3.
3. Bernatchez PN, Sharma A, Kodaman P, et al., Myoferlin is critical for endocytosis in endothelial cells. Am J Physiol Cell Physiol 2009; 297: C484-92.
4. Bernatchez PN, Acevedo L, Fernandez-Hernando C, et al., Myoferlin regulates vascular endothelial growth factor receptor-2 stability and function. J Biol Chem 2007; 282: 30745-53.
5. Lek A, Evesson FJ, Sutton RB, et al., Ferlins: regulators of vesicle fusion for auditory neurotransmission, receptor trafficking and membrane repair. Traffic 2012; 13: 185-94.
6. Leung C, Yu C, Lin MI, et al., Expression of myoferlin in human and murine carcinoma tumors: role in membrane repair, cell proliferation, and tumorigenesis. Am J Pathol 2013; 182: 1900-9.
7. Rodriguez JA, Li M, Yao Q, et al., Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications. World J Surg 2005; 29: 297-305.
8. Iacobuzio-Donahue CA, Maitra A, Olsen M, et al., Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 2003; 162: 1151-62.
9. Badea L, Herlea V, Dima SO, et al., Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology 2008; 55: 2016-27.
10. Turtoi A, Musmeci D, Wang Y, et al., Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma. J Proteome Res 2011; 10: 4302-13.
11. Wang WS, Liu XH, Liu LX, et al., ITRAQ-based quantitative proteomics reveals myoferlin as a novel prognostic predictor in pancreatic adenocarcinoma. J Proteomics 2013; 91: 453-65.
12. McKinney KQ, Lee YY, Choi HS, et al., Discovery of putative pancreatic cancer biomarkers using subcellular proteomics. J Proteomics 2011; 74: 79-88.
13. Eisenberg MC, Kim Y, Li R, et al., Mechanistic modeling of the effects of myoferlin on tumor cell invasion. Proc Natl Acad Sci USA 2011; 108: 20078-83.
14. Li R, Ackerman WEIV, Mihai C, et al., Myoferlin depletion in breast cancer cells promotes mesenchymal to epithelial shape change and stalls invasion. PLoS ONE 2012; 7: e39766.
15. Volakis LI, Li R, Ackerman WEIV, et al., Loss of myoferlin redirects breast cancer cell motility towards collective migration. PLoS ONE 2014; 9: e86110.
16. Turtoi A, Blomme A, Bellahcène A, et al., Myoferlin is a key regulator of EGFR activity in breast cancer. Cancer Res 2013; 73: 5438-48.
17. Peulen O, Gonzalez A, Peixoto P, et al., The anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2. PLoS ONE 2013; 8: e75102.
18. Peixoto P, Castronovo V, Matheus N, et al., HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells. Cell Death Differ 2012; 19: 1239-52.
19. Bolte S, Cordelières FP., A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 2006; 224: 213-32.
20. Barəu A, Ruiz-Sauri A, Valencia G, et al., High microvessel density in pancreatic ductal adenocarcinoma is associated with high grade. Virchows Arch 2013; 462: 541-6.
21. Gadaleta E, Cutts RJ, Kelly GP, et al., A global insight into a cancer transcriptional space using pancreatic data: importance, findings and flaws. Nucleic Acids Res 2011; 39: 7900-7.
22. Stratford JK, Bentrem DJ, Anderson JM, et al., A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med 2010; 7: e1000307.
23. Aguirre-Gamboa R, Gomez-Rueda H, Martínez-Ledesma E, et al., SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS ONE 2013; 8: e74250.
24. Itakura J, Ishiwata T, Shen B, et al., Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000; 85: 27-34.
25. Luo J, Guo P, Matsuda K, et al., Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer 2001; 92: 361-9.
26. Marty NJ, Holman CL, Abdullah N, et al., The C2 domains of otoferlin, dysferlin, and myoferlin alter the packing of lipid bilayers. Biochemistry 2013; 52: 5585-92.
27. Reinmuth N, Parikh AA, Ahmad SA, et al., Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech 2003; 60: 199-207.
28. Seo Y, Baba H, Fukuda T, et al., High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000; 88: 2239-45.
29. Marschall von Z, Cramer T, Höcker M, et al., De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 2000; 119: 1358-72.
30. Kindler HL, Friberg G, Singh DA, et al., Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23: 8033-40.
31. Bockhorn M, Tsuzuki Y, Xu L, et al., Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin Cancer Res 2003; 9: 4221-6.
32. Doherty KR., Normal myoblast fusion requires myoferlin. Development 2005; 132: 5565-75.
33. Roux I, Safieddine S, Nouvian R, et al., Otoferlin, defective in a human deafness form, is essential for exocytosis at the auditory ribbon synapse. Cell 2006; 127: 277-89.
34. Davis DB, Doherty KR, Delmonte AJ, et al., Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains. J Biol Chem 2002; 277: 22883-8.
35. Redpath GMI, Woolger N, Piper AK, et al., Calpain cleavage within dysferlin exon 40a releases a synaptotagmin-like module for membrane repair. Mol Biol Cell 2014; 25: 3037-48.
36. Tucker WC, Chapman ER., Role of synaptotagmin in Ca2+-triggered exocytosis. Biochem J 2002; 366: 1-13.
37. Ikeda N, Adachi M, Taki T, et al., Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999; 79: 1553-63.
38. Karayiannakis AJ, Bolanaki H, Syrigos KN, et al., Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 2003; 194: 119-24.
39. Niedergethmann M, Hildenbrand R, Wostbrock B, et al., High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002; 25: 122-9.
40. Hoem D, Straume O, Immervoll H, et al., Vascular proliferation is associated with survival in pancreatic ductal adenocarcinoma. Apmis 2013; 121: 1037-46.
41. Andreozzi M, Quagliata L, Gsponer JR, et al., VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities. Angiogenesis 2014; 17: 519-27.
42. Martin LK, Li X, Kleiber B, et al., VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. Ann Oncol 2012; 23: 2812-20.
43. Kindler HL, Niedzwiecki D, Hollis D, et al., Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-22.
44. Kindler HL, Ioka T, Richel DJ, et al., Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011; 12: 256-62.
45. Van Cutsem E, Jayson G, Dive C, et al., Analysis of blood plasma factors in the AVITA Phase III randomized study of bevacizumab (bev) with gemcitabine-erlotinib (GE) in patients (pts) with metastatic pancreatic cancer (mPC). Eur J Cancer 2011; 47: S95-6.
46. Yu C, Sharma A, Trane A, et al., Myoferlin gene silencing decreases Tie-2 expression in vitro and angiogenesis in vivo. Vascul Pharmacol 2011; 55: 26-33.
47. Demonbreun AR, Posey AD, Heretis K, et al., Myoferlin is required for insulin-like growth factor response and muscle growth. Faseb J 2010; 24: 1284-95.
48. Oikawa T, Hitomi J, Kono A, et al., Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells. Int J Pancreatol 1995; 18: 15-23.
49. Taeger J, Moser C, Hellerbrand C, et al., Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther 2011; 10: 2157-67.
50. Wong MH, Xue A, Julovi SM, et al., Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Clin Cancer Res 2014; 20: 4047-58.